|
|
|
|
|
|
|
|
|
|
|
|
|
10.09.26 - 09:15
|
Alchemab Therapeutics Expands Leadership Team, Appointing Dr Ben Porter-Brown as CMO to Propel the Clinical Advancement of Its Pipeline (Business Wire)
|
|
|
CAMBRIDGE, England--(BUSINESS WIRE)--Clinical-stage biotech Alchemab Therapeutics has appointed experienced pharma and biotech leader Dr Ben Porter-Brown as Chief Medical Officer (CMO) to accelerate the clinical development of the company's pipeline of highly novel antibody therapeutics.
Alchemab is discovering and developing first-in-class drugs through its Resiliome™ platform, which combines the world's largest immune database derived from disease-resilient individuals with advanced AI and lab validation to identify naturally occurring protective auto-antibodies in people with unusual resistance to hard-to-treat diseases.
The company's first asset, ATLX-1282 – a first-in-class drug for ALS licensed to Eli Lilly and Company – progressed from discovery to the clinic in less than three years, highlighting the power of Alchemab's human-first approach. Initiation of a Phase 1 trial for ATLX-2847 – a first-in-class PGDH inhibitor for muscle atrophy – is anticipated by the end of 2026, with a dee...
|
|
|
|
|
09.09.26 - 11:01
|
Amgen: Heftiger Kursrutsch – das ist der Grund (Der Aktionaer)
|
|
|
Das war heftig: Die Aktie von Amgen brach am Dienstag massiv ein. Mit einem Minus von mehr als zehn Prozent war das Papier der mit Abstand größte Verlierer im US-Leitindex Dow Jones. Das Unternehmen gilt neben Novo Nordisk und Eli Lilly auch als Hoffnungsträger im Bereich Adipositas....
|
|
|
|
|
|
|
|
|
08.09.26 - 14:06
|
Moonwalk Biosciences Announces $70 Million Series B Financing to Advance Adipose-Targeted RNAi Therapies for Obesity and Cardiometabolic Diseases (Business Wire)
|
|
|
Financing co-led by Alpha Wave and YK Bioventures, with participation from Eli Lilly and Company, Gaorong Ventures and existing investors ARCH Venture Partners, Khosla Ventures and Future Ventures
Proceeds will advance Moonwalk's lead obesity program into the clinic and accelerate a pipeline of adipose-selective RNAi medicines targeting novel biology
Dr. Stephen Djedjos appointed Senior Vice President, Clinical DevelopmentSOUTH SAN FRANCISCO & SAN DIEGO--(BUSINESS WIRE)--#biotech--Moonwalk Biosciences, a biotechnology company developing first-in-class adipose-targeted RNA interference (RNAi) medicines for obesity and cardiometabolic diseases, today announced the closing of an oversubscribed $70 million Series B financing.
The financing was co-led by Alpha Wave and YK Bioventures, with participation from Eli Lilly and Company, Gaorong Ventures, and existing investors ARCH Venture Partners, Khosla Ventures and Future Ventures. Proceeds will support advancement of Moonwalk's lead obesity candidate, MW101, ...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
